for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Shanghai Pharmaceuticals Holding Co Ltd

601607.SS

Latest Trade

17.69CNY

Change

0.05(+0.28%)

Volume

4,400,766

Today's Range

17.55

 - 

17.72

52 Week Range

15.79

 - 

23.66

As of on the Shanghai Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
17.64
Open
17.63
Volume
4,400,766
3M AVG Volume
185.06
Today's High
17.72
Today's Low
17.55
52 Week High
23.66
52 Week Low
15.79
Shares Out (MIL)
2,842.09
Market Cap (MIL)
45,761.85
Forward P/E
11.93
Dividend (Yield %)
2.32

Latest Developments

More

Shanghai Pharmaceuticals' 9-Month Net Profit Up 0.8% Y/Y

Shanghai Pharmaceuticals Holding Received Reply From CSRC

Shanghai Pharma's Unit To Set Up JV With BIOCAD Holding Hong Kong

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Shanghai Pharmaceuticals Holding Co Ltd

Shanghai Pharmaceuticals Holding Co., Ltd. is a China-based company principally engaged in the manufacture and sales of pharmaceuticals. The Company's businesses include the research and registration, production, sales, distribution and retailing of pharmaceutical products, among others. Its products are applied in cardiovascular system, anti-cancer and immunoregulation, anti-infection and metabolism, as well as other fields. The Company operates businesses in domestic and overseas markets.

Industry

Major Drugs

Contact Info

Shanghai Pharmaceutical Mansion

No.200 Taicang Road

+86.21.63730908

http://www.sphchina.com/

Executive Leadership

Jun Zhou

Chairman of the Board, Non-Executive Director

Min Zuo

President, Executive Director

Bo Shen

Chief Financial Officer, Vice President, Executive Director

Yongzhong Li

Vice President, Executive Director

Dawei Liu

Vice President, Secretary of the Board

Key Stats

2.27 mean rating - 15 analysts
Sell
Hold
Buy
Revenue (MM, CNY)

2016

120.8K

2017

130.8K

2018

159.1K

2019(E)

186.1K
EPS (CNY)

2016

1.190

2017

1.309

2018

1.372

2019(E)

1.483
Price To Earnings (TTM)
12.83
Price To Sales (TTM)
0.25
Price To Book (MRQ)
1.23
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
87.73
LT Debt To Equity (MRQ)
25.37
Return on Investment (TTM)
9.39
Return on Equity (TTM)
3.49

Latest News

Latest News

BRIEF-Shanghai Pharmaceuticals Holding to pay cash dividend of 3.8 yuan (pre-tax) for every 10 shares

* Says it plans to pay a cash dividend of 3.8 yuan (pre-tax) for every 10 shares as the dividend payment plan for 2017

BRIEF-Shanghai Pharmaceuticals Holding unit receives GMP certificate

* Says co's Shanghai-based wholly owned unit received goods manufacture practice (GMP) certificate from Shanghai Food and Drug Administration, for therapeutic biological products

Shanghai Pharmaceuticals plans $400 mln share sale to fund production

Shanghai Pharmaceuticals Holding Co Ltd said on Friday it planned to sell HK$3.13 billion ($400 million) worth of new shares to fund the development of its manufacturing and distribution businesses.

BRIEF-Shanghai Pharmaceuticals Holding units receive GMP certificate

* Says Changzhou-based pharmaceuticals unit received goods manufacture practice (GMP) certificate from Jiangsu Food and Drug Administration, for its products including acyclovir, ganciclovir and production line

BRIEF-Shanghai Pharmaceuticals Holding unit receives GMP certificate

* Says its unit received goods manufacture practice (GMP) certificate from Shandong Food and Drug Administration, for its products including mixture, oral liquid, drops and bulk drug

BRIEF-Shanghai Pharmaceuticals Holding Announces ‍CSRC's Approval On Issuance Of New Shares

* ANNOUNCES CSRC'S APPROVAL ON ISSUANCE OF NEW 153.2 MILLION H SHARES AT VALUE OF RMB1 PER SHARE Source text for Eikon: Further company coverage:

BRIEF-Shanghai Pharmaceuticals Gets Regulatory Approval To Issue Up To 153.2 Mln H-Shares

* SAYS IT GETS SECURITIES REGULATOR'S APPROVAL TO ISSUE UP TO 153.2 MILLION H-SHARES Source text in Chinese: http://bit.ly/2C81gx7 Further company coverage: (Reporting by Hong Kong newsroom)

BRIEF-Shanghai Pharmaceuticals Holding To Transfer Entire Stake In Shanghai Huashi Asset Management

* ANNOUNCES TRANSFER OF 100% EQUITY INTEREST IN SHANGHAI HUASHI ASSET MANAGEMENT CO TO A CONTROLLING SHAREHOLDER

BRIEF-Shanghai Pharmaceuticals Holding unit receives GMP certificate

* Says its wholly owned unit received goods manufacture practice (GMP) certificate from Shanghai Food and Drug Administration

BRIEF-Shanghai Pharmaceuticals Holding unit receives GMP certificate

* Says its Shanghai-based unit received goods manufacture practice (GMP) certificate from Shanghai Food and Drug Administration

BRIEF-Shanghai Pharmaceuticals Holding unit receives GMP certificate

* Says its wholly owned unit received goods manufacture practice (GMP) certificate from Shanghai Food and Drug Administration

BRIEF-Shanghai Pharmaceuticals Holding unit to take out loan of $100 mln

* Says co's Hong Kong-based wholly owned unit will take out loan of $100 million (about 664 million yuan) form co's controlling shareholder, with term of 180 days

Shanghai Pharma buys U.S. Cardinal Health's China business for $557 million

Shanghai Pharmaceuticals Holding Co has agreed to buy Cardinal Health Inc's China drug distribution business for $557 million, winning a highly competitive auction in a move that will greatly expand its presence nationwide.

Shanghai Pharma buys U.S. Cardinal Health's China business for $557 mln

State-owned Shanghai Pharmaceuticals Holding Co has agreed to acquire Cardinal Health Inc's China business, one of the nation's largest drug distributors, for $557 million.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up